WO1999054954A3 - Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections - Google Patents

Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections Download PDF

Info

Publication number
WO1999054954A3
WO1999054954A3 PCT/DE1999/001177 DE9901177W WO9954954A3 WO 1999054954 A3 WO1999054954 A3 WO 1999054954A3 DE 9901177 W DE9901177 W DE 9901177W WO 9954954 A3 WO9954954 A3 WO 9954954A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
pharmaceuticals
radio
radioimmunological
eliminated
Prior art date
Application number
PCT/DE1999/001177
Other languages
German (de)
French (fr)
Other versions
WO1999054954A2 (en
Inventor
Wolfgang Bergter
Ingrid Corinna Bergter
Original Assignee
Wolfgang Bergter
Ingrid Corinna Bergter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998126307 external-priority patent/DE19826307A1/en
Application filed by Wolfgang Bergter, Ingrid Corinna Bergter filed Critical Wolfgang Bergter
Priority to AU44971/99A priority Critical patent/AU4497199A/en
Priority to DE19980721T priority patent/DE19980721D2/en
Priority to JP2000545211A priority patent/JP2002512261A/en
Priority to EP99927685A priority patent/EP1071475A2/en
Publication of WO1999054954A2 publication Critical patent/WO1999054954A2/en
Publication of WO1999054954A3 publication Critical patent/WO1999054954A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The disadvantages of standard HIV therapies are as follows: currently used medicaments must be taken in large quantities each day during an entire lifetime according to a strict timetable and have a large number of side effects. Traditional medicaments only manage to restrict virus replication. Host cells infected with HIV are not eliminated. For this reason it was not previously possible to cure HIV infections. The current application describes, as an additional application to PCT patent application (PCT/DE99/00598) dated 8.3.99, radio-immunological pharmaceuticals consisting of a CD4 molecule or a fragment derived therefrom and a radionuclide for in-vivo elimination of HIV replicating cells in HIV-1 and HIV-2 infected patients. The combination of HIV affine CD4 receptor molecules or fragments with radionuclides for therapeutic purposes, especially for use in radioimmunological anti-HIV therapy is totally novel. The radioimmunological pharmaceuticals are to be administered intravenously to HIV-1 or HIV-2 infected patients once or in several cycles in order to cause sustained damage to HIV replicating cells in a targeted manner so that the latter can be fully eliminated.
PCT/DE1999/001177 1998-04-15 1999-04-15 Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections WO1999054954A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU44971/99A AU4497199A (en) 1998-04-15 1999-04-15 Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections
DE19980721T DE19980721D2 (en) 1998-04-15 1999-04-15 CD4 radioimmunopharmaceuticals used to treat HIV infection
JP2000545211A JP2002512261A (en) 1998-04-15 1999-04-15 CD4 radioimmune drug for treating HIV infection
EP99927685A EP1071475A2 (en) 1998-04-15 1999-04-15 Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19826307.4 1998-04-15
DE1998126307 DE19826307A1 (en) 1998-03-08 1998-04-15 CD4 radio immunological pharmaceuticals

Publications (2)

Publication Number Publication Date
WO1999054954A2 WO1999054954A2 (en) 1999-10-28
WO1999054954A3 true WO1999054954A3 (en) 2000-01-20

Family

ID=7870747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/001177 WO1999054954A2 (en) 1998-04-15 1999-04-15 Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections

Country Status (5)

Country Link
EP (1) EP1071475A2 (en)
JP (1) JP2002512261A (en)
AU (1) AU4497199A (en)
DE (1) DE19980721D2 (en)
WO (1) WO1999054954A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004050A1 (en) * 1989-09-14 1991-04-04 Board Of Regents, The University Of Texas System Therapeutic compositions; methods for treatment of hiv infections
WO1991011461A1 (en) * 1990-01-26 1991-08-08 Biogen, Inc. C4 binding protein fusion proteins
WO1994004191A1 (en) * 1992-08-13 1994-03-03 Antisoma Limited Medical treatment
WO1997003198A2 (en) * 1995-07-07 1997-01-30 Texas A & M University System Nucleotide and amino acid sequence and uses thereof
WO1999045969A2 (en) * 1998-03-08 1999-09-16 Wolfgang Bergter Radioimmuno-pharmacon for treating the hiv-1 infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004050A1 (en) * 1989-09-14 1991-04-04 Board Of Regents, The University Of Texas System Therapeutic compositions; methods for treatment of hiv infections
WO1991011461A1 (en) * 1990-01-26 1991-08-08 Biogen, Inc. C4 binding protein fusion proteins
WO1994004191A1 (en) * 1992-08-13 1994-03-03 Antisoma Limited Medical treatment
WO1997003198A2 (en) * 1995-07-07 1997-01-30 Texas A & M University System Nucleotide and amino acid sequence and uses thereof
WO1999045969A2 (en) * 1998-03-08 1999-09-16 Wolfgang Bergter Radioimmuno-pharmacon for treating the hiv-1 infection

Also Published As

Publication number Publication date
EP1071475A2 (en) 2001-01-31
WO1999054954A2 (en) 1999-10-28
DE19980721D2 (en) 2001-03-29
AU4497199A (en) 1999-11-08
JP2002512261A (en) 2002-04-23

Similar Documents

Publication Publication Date Title
CY1119369T1 (en) MEDICAL PREPARATIONS FOR THE THERAPEUTIC TREATMENT OF ALPHA-MILK DISEASE
HUP0104717A2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
BR9912653A (en) Attenuated herpes virus, virus strain, dendritic cell, process to produce a cell, pharmaceutical composition, use of a virus, and process to perform gene therapy on a human or animal patient or to treat or prevent a pathogenic infection or cancer to treat animal patient
NZ601544A (en) Combination therapy for the treatment of ocular neovascular disorders
TW265265B (en)
DK0751781T3 (en) Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic diseases
NO20015584L (en) Long-lasting insulin-tropic peptides and conjugates and use in the manufacture of medicaments for treatment
Sillanpää Clonidine prophylaxis of childhood migraine and other vascular headache: a double blind study of 57 children
EP0330227A3 (en) Derivatives of soluble t-4
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
BR9808100A (en) Use of amandantine to treat hepatitis c.
CA2315277A1 (en) Pharmaceutical compositions containing the long pentraxin ptx3
HK1068606A1 (en) Novel aminobenzoephenones
JPS55151566A (en) 66substitutedd111alkyleneemorphanthridine* its manufacture and medicine containing it
WO1999054954A3 (en) Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections
ZA202304877B (en) Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
YU56702A (en) Use of fsh for treating infertility
TR199901958T2 (en) A medicine against infertility and to increase fertility.
ATE554793T1 (en) CONJUGATE
BR0212928A (en) Process for treating hapatitis c viral infection in non-responders
EA199800770A1 (en) DRUGS FOR THERAPEUTIC TREATMENT OF VIRAL HEPATITIS
BR0015329A (en) Use of nitric oxide for the treatment of airway constriction
TR200000728T2 (en) The use of IFN-alpha and amantadine in the treatment of chronic hepatitis C.
Lavaroni et al. Hallopeau's acrodermatitis treated with cyclosporin Aa case report
James T-20: entirely new antiretroviral

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09673557

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999927685

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999927685

Country of ref document: EP

REF Corresponds to

Ref document number: 19980721

Country of ref document: DE

Date of ref document: 20010329

WWE Wipo information: entry into national phase

Ref document number: 19980721

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999927685

Country of ref document: EP